Atopic Eczema Clinical Trial
Official title:
A Study to Evaluate the Performance of Adex Gel in the Treatment of Atopic Eczema Using SCORAD and Quality of Life Assessments.
This is a prospective, open label, uncontrolled study which will be performed in multiple Primary Care (GP) centres, in approximately 60 children (aged 1 year to 15 years) who have moderate atopic eczema and who are not currently using oral or topical corticosteroids or immunomodulators and have not used them in the previous month. Study patients will be asked to use Adex Gel three times daily, for 4 weeks instead of their usual emollient or as the first treatment for their condition, and without supplementary use of any oral or topical steroids or immunomodulators (unless this becomes unavoidable, see section 4.6.3). The Scoring Atopic Dermatitis (SCORAD) assessment will be performed by the investigator/ research nurse at baseline and then after 2 and 4 weeks of treatment. Patients or their parents/ guardians will be asked to complete the quality-of-life questionnaires (Children's Dermatology Life Quality Index (CDLQI) at baseline and after 4 weeks of treatment. Photographs, which will not include any identifiable features or details of the patient, of one eczema affected area will also be taken at baseline and again 4 weeks after treatment.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Year to 15 Years |
Eligibility | Inclusion Criteria: - Male or female. - Aged between 1 year and 15 years. - Patients with atopic eczema (personal or combined personal and familial atopy), of moderate severity in accordance with the NICE categorisation - SCORAD assessment score of between 25 to 50. - Minimum score of 6 on the CDLQI (QoL). - Patients or their parents/ legal guardians must be able to read and understand the patient information sheet and sign the consent form. - Patients normally managing their eczema by regular and ongoing use of leave-on emollient(s), or new atopic eczema sufferers, who have not been using oral or topical corticosteroids, Adex Gel or immunomodulators for the last month. - Patients who are willing to use only Adex Gel for 4 weeks. - Patients who are willing to continue to use their standard wash regime for the duration of the study. This will be documented at the initial visit. Exclusion Criteria: - Under 1 year of age or over 15 years and 11 months at screening. - Are currently using or have used in the past month, any oral or topically applied corticosteroids, Adex Gel or immunomodulators for their atopic eczema. - Have a known history of intolerance or skin sensitivity to any of the ingredients of Adex Gel (as identified on the patient information sheet and product labelling), or similar products. - Have mild eczema. - Have severe or potentially infected eczema. - Participating in other ongoing studies or have participated in a study in the previous 30 days. - Patients, or their parents/ legal guardians, who may have difficulties completing the quality-of-life questionnaire, which will be written in English only. - Employees of the Sponsor or Investigators, or any immediate family member (partner, offspring, parents, siblings, or sibling's offspring) of such employees. - Patients with any medical condition which, in the opinion of the Investigator, may adversely influence their participation in the study. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Atherstone Surgery | Atherstone | Warwickshire |
United Kingdom | Cripps Health Centre | Nottingham | Nottinghamshire |
Lead Sponsor | Collaborator |
---|---|
Dermal Laboratories Ltd |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | SCORAD | Change in SCORAD (SCORing Atopic Dermatitis, based on Area, Intensity and Subjective score. (Score of 0-103 with the higher the score the more severe the condition)) over 4 weeks. | 4 weeks | |
Primary | QoL | Change in CDLQI (Child Dermatology Quality of Life Index (a maximum score of 30 and a minimum score of 0. The higher the score, the more quality of life is effected)) over 4 weeks | 4 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02381028 -
Topical Treatment With Fresh Human Milk Versus Emollient on Atopic Eczema Spots in Young Children
|
N/A | |
Completed |
NCT00484003 -
A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis
|
Phase 4 | |
Recruiting |
NCT06230991 -
A Pilot Study of Efficacy and Safety of SIM05 in Adults With Atopic Eczema
|
N/A | |
Completed |
NCT01854580 -
Evaluation of an Integrated Care Project
|
||
Completed |
NCT00555178 -
Regulatory T Cells (Tregs) in Polymorphic Light Eruption
|
N/A | |
Completed |
NCT00559546 -
Montelukast as a Controller of Atopic Syndrome
|
Phase 4 | |
Completed |
NCT00224432 -
Double-Blind, Parallel, Randomised Study to Investigate the Effect of Oral Probiotics in Infants With Atopic Dermatitis
|
N/A | |
Active, not recruiting |
NCT03143504 -
A Longitudinal Investigation of Skin Barrier Development From Birth and the Validation of Early Predictors of Atopic Eczema Risk: the Skin Testing for Atopic Eczema Risk (STAR) Study
|
||
Active, not recruiting |
NCT03409367 -
A Community-based Assessment of Skin Care, Allergies, and Eczema
|
N/A | |
Completed |
NCT00826592 -
Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis
|
N/A | |
Completed |
NCT00576238 -
Skin Tolerance Study of Betamethasone Creams in Atopic Eczema and the Preventative Properties of a Moisturiser
|
Phase 3 | |
Recruiting |
NCT05590585 -
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
|
Phase 4 | |
Completed |
NCT01119313 -
Study to Investigate Skin Conditions and Patient Assessment of LAS 41002 in the Treatment of Atopic Eczema
|
Phase 2 | |
Completed |
NCT00676884 -
A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema
|
Phase 2 | |
Recruiting |
NCT03270566 -
Softened Water for Eczema Prevention Pilot Trial
|
N/A | |
Completed |
NCT02300701 -
Role of Anti-IgE in Severe Childhood Eczema
|
Phase 4 | |
Completed |
NCT04114097 -
The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover
|
Phase 4 | |
Completed |
NCT02915146 -
Narrowband Ultraviolet B Versus Narrowband Ultraviolet B Plus Ultraviolet A1 for Atopic Eczema
|
N/A | |
Recruiting |
NCT00771121 -
Effect of Moisturizing Creams on Skin Barrier Function
|
Phase 4 | |
Completed |
NCT01179529 -
Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage
|
Phase 2 |